For instance, the level of PD-L1 expression can direct the selection of ICI therapy protocols in liver cancer patients, as suggested by the KEYNOTE-224 study, in which pembrolizumab showed superior efficacy in patients with higher levels of PD-L1 expression (27). Here, CD274 is linked to liver cancer.